Adagene ADAG
NASDAQ ADAG
$3.62 -0.07 (-1.89%)
As of: Sep 4, 2026 · 2:49 PM EDT

Adagene (ADAG) Other Non-Current Liabilities (2020 - 2026)

Adagene (ADAG) posted quarterly Other Non-Current Liabilities of $205.1 billion for Q4 2025, up 641.16% quarter-over-quarter from $27.7 billion in Q2 2023.

Analysis

Adagene (ADAG) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends

Adagene (ADAG) has reported Other Non-Current Liabilities for 5 consecutive years, with $205.1 billion the latest figure, recorded in Q4 2025.

  • In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $205.1 billion; the TTM figure through Dec 2025 stood at $205.1 billion (changed N/A YoY), while the FY2025 annual figure was $205.1 billion, changed N/A from the prior year.
  • Other Non-Current Liabilities advanced to $205.1 billion in Q4 2025 per ADAG's latest filing, from $27.7 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $205.1 billion in Q4 2025 and bottomed at $61919.0 in Q2 2021.
  • Historically, Other Non-Current Liabilities has averaged $48.6 billion across 4 years, with a median of $28.2 billion in 2022.
  • Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 48127292.24% — and 2023, when it decreased 7.12%.
  • Adagene's Other Non-Current Liabilities stood at $94107.0 in 2021, then jumped by 30516227.16% to $28.7 billion in 2022, then decreased by 3.62% to $27.7 billion in 2023, then jumped by 641.16% to $205.1 billion in 2025.
  • Business Quant data shows ADAG's Other Non-Current Liabilities at $205.1 billion in Q4 2025, $27.7 billion in Q2 2023, and $28.7 billion in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn
5 Revolution Medicines 44.02 Bn 44.02 Bn -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn
8 Royalty Pharma 28.43 Bn 27.59 Bn -
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
10 Adagene 213.60 Mn 213.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.18 Mn
Dec 31, 2025 205,146.00
Jun 30, 2023 27,679.00
Dec 31, 2022 28,718.00
Jun 30, 2022 29,800.00
Dec 31, 2021 94,107.00
Jun 30, 2021 61,919.00
Dec 31, 2020 91,955.00